Effects of a 3-mo consumption of short-chain fructo-oligosaccharides on parameters of colorectal carcinogenesis in patients with or without small or large colorectal adenomas.
Intervention studies of colorectal adenoma recurrence have demonstrated the need for surrogate markers of the cancer risk. Short-chain fructo-oligosaccharides (sc-FOS) have protective actions on colon carcinogenesis in animal models. We investigated differences in biological markers between adenoma and adenoma-free subjects, before and after 3 mo of daily intake of 10 g sc-FOS, within a multicenter study. After a full colonoscopy, 3 groups were studied at baseline and after 3 mo: 26 subjects with small colorectal adenoma(s), 18 with large adenoma(s), and 30 with no adenoma. At baseline, the mean fecal butyrate concentration was significantly lower in the adenoma groups than in the adenoma-free group (12.01 +/- 5.08 vs. 17.28 +/- 7.34 mmol/g dry weight) but was significantly increased in that group after 3-mo ingestion of sc-FOS (15.7 +/- 8.0 mmol/g; P = 0.02). In subjects without adenoma, sc-FOS ingestion was associated with a decrease in fecal lithocholic acid (P = 0.02) and an increase in cholic acid (P = 0.02), chenodeoxycholic acid (P = 0.04), total primary bile acids (P = 0.03), and ursodeoxycholic acid (P = 0.05). Fecal pH, blood parameters, and crypt cell proliferation were not significantly modified by sc-FOS ingestion in either group. In subjects with and without adenoma, sc-FOS affects some aspects of the colonic environment, which may be involved in prevention of colorectal neoplasia.
Nutrition, Hormones and Cancer Unit, E3N, EMT, Institut Gustave Roussy, 94805 Villejuif Cedex, France. boutron@igr.fr
Marie-Christine
MC
Boutron-Ruault
Philippe
P
Marteau
Anne
A
Lavergne-Slove
Anne
A
Myara
Marie-France
MF
Gerhardt
Claire
C
Franchisseur
Francis
F
Bornet
D000236:Adenoma / Q000188:drug therapy* / Q000453:epidemiology / Q000473:pathology; D000328:Adult; D000368:Aged; D001647:Bile Acids and Salts / Q000378:metabolism; D015415:Biomarkers; D002087:Butyrates / Q000032:analysis; D002455:Cell Division / Q000187:drug effects; D003113:Colonoscopy; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000453:epidemiology / Q000473:pathology; D005243:Feces / Q000737:chemistry*; D005260:Female; D006801:Humans; D006863:Hydrogen-Ion Concentration; D008297:Male; D008875:Middle Aged; D009844:Oligosaccharides / Q000494:pharmacology*; D012307:Risk Factors; D014580:Ursodeoxycholic Acid / Q000032:analysis
D001647:Bile Acids and Salts; D015415:Biomarkers; D002087:Butyrates; D009844:Oligosaccharides; C116580:fructooligosaccharide; D014580:Ursodeoxycholic Acid